The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function
Thyroid® · 2024
DOI: 10.1089/thy.2023.0542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thyroid®, 2024. Verfasst von Karen Tsai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Metabolism, City of Hope Comprehensive Cancer Center, Duarte, California, USA. Hauptthemen laut MEDLINE: Hypothyroidism, Thyroid Diseases, Hyperthyroidism, Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Background
Recent successes with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) for the treatment of solid malignancies have paved the way for a new era of combined therapy. A common side effect seen with each of these classes of treatment is thyroid dysfunction, with rates estimated at 30-40% for TKI and 10-20% for ICI. However, little is known about the effect of combined ICI+TKI therapy on thyroid function. Therefore, this study evaluated the incidence, clinical features, and risk factors for developing thyroid abnormalities during ICI+TKI therapy and the relationship to cancer outcomes.
Methods
We conducted a retrospective cohort study of patients treated with combination ICI+TKI cancer therapy at City of Hope Comprehensive Cancer Center from 2017 to 2023 who had pretreatment normal thyrotropin (TSH) levels. Primary analyses assessed the frequency, timing, and severity of thyroid function test abnormalities during ICI+TKI cancer therapy, and the requirement for thyroid hormone replacement. Secondary analyses evaluated risk factors for the development of thyroid dysfunction, including sex and drug regimen, and the association with cancer progression-free survival or overall survival. Univariable and multivariable models were used.
Results
There were 106 patients who received ICI+TKI therapy with a median age of 63.5 years and a median follow-up of 12.8 months (interquartile range [IQR] 5.9-20.9). Notably, 63.2% (67/106) developed thyroid function abnormalities during ICI+TKI therapy, including 11 (10.4%) with hyperthyroidism, 42 (39.6%) with subclinical hypothyroidism (SCHypo), and 14 (13.2%) with overt hypothyroidism. The onset of thyroid dysfunction occurred at a median of 7 weeks (IQR 3.1-9.0) after start of ICI+TKI treatment for hyperthyroidism, 8.0 weeks (IQR 3.0-19.0) for SCHypo, and 8.1 weeks (IQR 5.9-9.1) for overt or worsening hypothyroidism. Hyperthyroidism resolved to hypothyroidism or normal TSH without intervention in all subjects, suggesting thyroiditis, and hypothyroidism was readily treated with thyroid hormone replacement.
Conclusions
Thyroid dysfunction is a frequent adverse event in individuals treated with combination ICI+TKI therapy, with our data suggesting a rapid onset and higher incidence than previously seen with ICI or TKI therapy alone. Therefore, close monitoring of thyroid function during initial therapy and multidisciplinary care with endocrinology are recommended to facilitate early detection and initiation of thyroid hormone replacement in these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology and Metabolism, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Division of Biostatistics, Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, California, USA.
- Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
- Department of Medical Oncology, and City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, California, USA.
- Division of Endocrinology, UCLA Geffen School of Medicine, Los Angeles, California, USA.
ORCID-Profile: Karen Tsai, Melissa G Lechner
Förderung
- NIDDK NIH HHS
Zitieren
APA
Tsai, K., Ma, H., Liang, T. Z., Xing, Y., Chung, S., Dorff, T., Bell, D., & Lechner, M. G. (2024). The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function. Thyroid®. https://doi.org/10.1089/thy.2023.0542
Vancouver
Tsai K, Ma H, Liang TZ, Xing Y, Chung S, Dorff T, et al. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function. Thyroid®. 2024. doi:10.1089/thy.2023.0542
BibTeX
@article{Tsai2024,
author = {Tsai, Karen and Ma, Huiyan and Liang, Tom Z and Xing, Yan and Chung, Samuel and Dorff, Tanya and Bell, Diana and Lechner, Melissa G},
title = {The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function},
journal = {Thyroid®},
year = {2024},
doi = {10.1089/thy.2023.0542}
}
EUVIMED